FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894040066> ?p ?o ?g. }

• W2894040066 endingPage "e96" @default.
• W2894040066 startingPage "e92" @default.
• W2894040066 abstract "Background Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itraconazole as a potentially noncastrating treatment approach in biochemically recurrent prostate cancer. Patients and Methods Patients with biochemically recurrent prostate cancer and PSADT ≤ 15 months, with serum testosterone > 150 ng/dL, were prospectively enrolled. The primary end point was the proportion of patients who experienced ≥ 50% decline from baseline in serum prostate-specific antigen (PSA) by week 12. Results Twenty-one patients were enrolled. The median (range) age, baseline PSA, and PSADT at study entry was 72 (49-76) years, 7.6 (1.5-45.5) ng/mL, and 5.7 (1.2-13.0) months, respectively. Among 19 patients with evaluable data, 1 patient (5%) had a > 50% PSA decline. Nine patients (47%) experienced any PSA decline (mean decline 25.0%, range 2%-60%) by week 12. Among 10 patients without a PSA decline, the on-treatment versus pretreatment PSADT was not significantly longer (median 6.8 vs. 4.3 months, P = .17). There was no significant change from baseline to week 12 in serum testosterone (median change = 32.4%, P = .21) or androstenedione (median change = −8.3%, P = .85). The most common adverse events were edema (52%), fatigue (38%), hypertension (24%), and hypokalemia (24%). Conclusion Itraconazole modulates serum PSA levels without lowering serum testosterone. However, the magnitude of effect is modest, and treatment carries risk of toxicities associated with mineralocorticoid excess." @default.
• W2894040066 created "2018-10-05" @default.
• W2894040066 creator A5003723594 @default.
• W2894040066 creator A5007578304 @default.
• W2894040066 creator A5012804612 @default.
• W2894040066 creator A5019669804 @default.
• W2894040066 creator A5024203592 @default.
• W2894040066 creator A5033609282 @default.
• W2894040066 creator A5043149483 @default.
• W2894040066 creator A5043368519 @default.
• W2894040066 creator A5054834158 @default.
• W2894040066 creator A5066716873 @default.
• W2894040066 creator A5073970384 @default.
• W2894040066 creator A5077000960 @default.
• W2894040066 creator A5079570071 @default.
• W2894040066 creator A5081123075 @default.
• W2894040066 date "2019-02-01" @default.
• W2894040066 modified "2023-09-24" @default.
• W2894040066 title "Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study" @default.
• W2894040066 cites W2020438145 @default.
• W2894040066 cites W2071124717 @default.
• W2894040066 cites W2081564236 @default.
• W2894040066 cites W2085368059 @default.
• W2894040066 cites W2089396531 @default.
• W2894040066 cites W2096600898 @default.
• W2894040066 cites W2098998490 @default.
• W2894040066 cites W2107270081 @default.
• W2894040066 cites W2119283349 @default.
• W2894040066 cites W2129509910 @default.
• W2894040066 cites W2135808678 @default.
• W2894040066 cites W2156034369 @default.
• W2894040066 cites W2166221624 @default.
• W2894040066 cites W2346524736 @default.
• W2894040066 cites W2775321189 @default.
• W2894040066 cites W4245845218 @default.
• W2894040066 doi "https://doi.org/10.1016/j.clgc.2018.09.013" @default.
• W2894040066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30327180" @default.
• W2894040066 hasPublicationYear "2019" @default.
• W2894040066 type Work @default.
• W2894040066 sameAs 2894040066 @default.
• W2894040066 citedByCount "17" @default.
• W2894040066 countsByYear W28940400662019 @default.
• W2894040066 countsByYear W28940400662020 @default.
• W2894040066 countsByYear W28940400662021 @default.
• W2894040066 countsByYear W28940400662022 @default.
• W2894040066 countsByYear W28940400662023 @default.
• W2894040066 crossrefType "journal-article" @default.
• W2894040066 hasAuthorship W2894040066A5003723594 @default.
• W2894040066 hasAuthorship W2894040066A5007578304 @default.
• W2894040066 hasAuthorship W2894040066A5012804612 @default.
• W2894040066 hasAuthorship W2894040066A5019669804 @default.
• W2894040066 hasAuthorship W2894040066A5024203592 @default.
• W2894040066 hasAuthorship W2894040066A5033609282 @default.
• W2894040066 hasAuthorship W2894040066A5043149483 @default.
• W2894040066 hasAuthorship W2894040066A5043368519 @default.
• W2894040066 hasAuthorship W2894040066A5054834158 @default.
• W2894040066 hasAuthorship W2894040066A5066716873 @default.
• W2894040066 hasAuthorship W2894040066A5073970384 @default.
• W2894040066 hasAuthorship W2894040066A5077000960 @default.
• W2894040066 hasAuthorship W2894040066A5079570071 @default.
• W2894040066 hasAuthorship W2894040066A5081123075 @default.
• W2894040066 hasConcept C121608353 @default.
• W2894040066 hasConcept C126322002 @default.
• W2894040066 hasConcept C126894567 @default.
• W2894040066 hasConcept C16005928 @default.
• W2894040066 hasConcept C197934379 @default.
• W2894040066 hasConcept C2776235491 @default.
• W2894040066 hasConcept C2777071850 @default.
• W2894040066 hasConcept C2777899217 @default.
• W2894040066 hasConcept C2778242168 @default.
• W2894040066 hasConcept C2779279991 @default.
• W2894040066 hasConcept C2779548794 @default.
• W2894040066 hasConcept C2780192828 @default.
• W2894040066 hasConcept C2781406297 @default.
• W2894040066 hasConcept C71924100 @default.
• W2894040066 hasConcept C90924648 @default.
• W2894040066 hasConceptScore W2894040066C121608353 @default.
• W2894040066 hasConceptScore W2894040066C126322002 @default.
• W2894040066 hasConceptScore W2894040066C126894567 @default.
• W2894040066 hasConceptScore W2894040066C16005928 @default.
• W2894040066 hasConceptScore W2894040066C197934379 @default.
• W2894040066 hasConceptScore W2894040066C2776235491 @default.
• W2894040066 hasConceptScore W2894040066C2777071850 @default.
• W2894040066 hasConceptScore W2894040066C2777899217 @default.
• W2894040066 hasConceptScore W2894040066C2778242168 @default.
• W2894040066 hasConceptScore W2894040066C2779279991 @default.
• W2894040066 hasConceptScore W2894040066C2779548794 @default.
• W2894040066 hasConceptScore W2894040066C2780192828 @default.
• W2894040066 hasConceptScore W2894040066C2781406297 @default.
• W2894040066 hasConceptScore W2894040066C71924100 @default.
• W2894040066 hasConceptScore W2894040066C90924648 @default.
• W2894040066 hasIssue "1" @default.
• W2894040066 hasLocation W28940400661 @default.
• W2894040066 hasLocation W28940400662 @default.
• W2894040066 hasOpenAccess W2894040066 @default.
• W2894040066 hasPrimaryLocation W28940400661 @default.
• W2894040066 hasRelatedWork W1992657261 @default.
• W2894040066 hasRelatedWork W2038565121 @default.

• next